Zone Model Predictive Control: A Strategy to Minimize Hyper- and Hypoglycemic Events
Зонное прогнозирующее управление моделью: стратегия минимизации эпизодов гипер- и гипогликемии
2010-07-01
SCID: 54.1/67a78w8t
Discuss with AI
artificial pancreascontinuous glucose monitoringinsulin deliverytype 1 diabetes mellituszone model predictive control
Figures from the paper
Abstract (AI)
BACKGROUND: Development of an artificial pancreas based on an automatic closed-loop algorithm that uses a subcutaneous insulin pump and continuous glucose sensor is a goal for biomedical engineering research. However, closing the loop for the artificial pancreas still presents many challenges, including model identification and design of a control algorithm that will keep the type 1 diabetes mellitus subject in normoglycemia for the longest duration and under maximal safety considerations. METHOD: An artificial pancreatic beta-cell based on zone model predictive control (zone-MPC) that is tuned automatically has been evaluated on the University of Virginia/University of Padova Food and Drug Administration-accepted metabolic simulator. Zone-MPC is applied when a fixed set point is not defined and the control variable objective can be expressed as a zone. Because euglycemia is usually defined as a range, zone-MPC is a natural control strategy for the artificial pancreatic beta-cell. Clinical data usually include discrete information about insulin delivery and meals, which can be used to generate personalized models. It is argued that mapping clinical insulin administration and meal history through two different second-order transfer functions improves the identification accuracy of these models. Moreover, using mapped insulin as an additional state in zone-MPC enriches information about past control moves, thereby reducing the probability of overdosing. In this study, zone-MPC is tested in three different modes using unannounced and announced meals at their nominal value and with 40% uncertainty. Ten adult in silico subjects were evaluated following a scenario of mixed meals with 75, 75, and 50 grams of carbohydrates (CHOs) consumed at 7 am, 1 pm, and 8 pm, respectively. Zone-MPC results are compared to those of the "optimal" open-loop preadjusted treatment. RESULTS: Zone-MPC succeeds in maintaining glycemic responses closer to euglycemia compared to the "optimal" open-loop treatment in te three different modes with and without meal announcement. In the face of meal uncertainty, announced zone-MPC presented only marginally improved results over unannounced zone-MPC. When considering user error in CHO estimation and the need to interact with the system, unannounced zone-MPC is an appealing alternative. CONCLUSIONS: Zone-MPC reduces the variability of control moves over fixed set point control without the need to detune the controller. This strategy gives zone-MPC the ability to act quickly when needed and reduce unnecessary control moves in the euglycemic range.
Key Findings
1
A zone model predictive control (zone-MPC) artificial pancreas was evaluated using the FDA-accepted University of Virginia/Padova metabolic simulator.
2
Across ten adult in silico subjects and announced or unannounced meals with up to 40% uncertainty, zone-MPC maintained glycemic responses closer to euglycemia than optimal open-loop preadjusted treatment.
3
Including mapped insulin as an additional zone-MPC state incorporates past control actions and is intended to reduce insulin overdosing risk.
4
Personalized model identification maps insulin administration and meal history through separate second-order transfer functions to improve identification accuracy.
5
Zone-MPC is suited to artificial pancreas control because euglycemia is defined as a target range rather than a fixed glucose set point.
Research Object
an artificial pancreas with a subcutaneous insulin pump and continuous glucose sensor for type 1 diabetes mellitus
Research Subject
the zone model predictive control strategy’s ability to maintain euglycemia and minimize hyperglycemic and hypoglycemic events under meal and insulin-delivery uncertainties
Publication Details
Publication Date
2010-07-01
Journal
Publisher
ISSN
Cited by
206
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes2009
Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: The Virginia Experience2009
Safety Constraints in an Artificial Pancreatic β Cell: An Implementation of Model Predictive Control with Insulin on Board2009
Cited by7
Individualized model predictive control for the artificial pancreas: In silico evaluation of closed-loop glucose control2018
Artificial Pancreas: Model Predictive Control Design from Clinical Experience2013
Closed-loop insulin delivery for treatment of type 1 diabetes2011
Adaptive Zone Model Predictive Control of Artificial Pancreas Based on Glucose- and Velocity-Dependent Control Penalties2018
An Insulin Infusion Advisory System Based on Autotuning Nonlinear Model-Predictive Control2011
In Silico Evaluation of an Artificial Pancreas Combining Exogenous Ultrafast-Acting Technosphere Insulin with Zone Model Predictive Control2013
Zone Model Predictive Control with Glucose- and Velocity-Dependent Control Penalty Adaptation for an Artificial Pancreas2018